Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Trump Media and Technology Group Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Trump Media and Technology Group Corp trades at $8.32 (market cap $2.48B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.8× Trump Media and Technology Group Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| BIO | DJT | |
|---|---|---|
Market Cap | $9.43B | $2.48B |
Sector | Health | Media |
52-Week High | $356.25 | $18.50 |
52-Week Low | $241.71 | $7.06 |
Enterprise Value | $9.18B | $2.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
DJT stock trades at $8.27, down 11.93% in the last session, reflecting bearish technical signals and fundamental challenges. The company reported Q2 2026 revenue of $1.67 million with a net loss of $238.1 million, driven by digital asset declines. Technical indicators show strong bearish momentum with support at $8 and resistance at $9-10 levels.
Outlook remains challenging with unsustainable valuation metrics (P/S ratio of 547.62) and persistent cash burn. Investment opportunities are limited given negative profitability and high business execution risks. Key risks include continued losses, competitive pressures, and volatile digital asset holdings affecting financial results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
